Personalized Melanoma Vaccine Evokes Immune Response
Key clinical point: Vaccination against patient-specific tumor neoantigens may represent a novel therapeutic strategy in melanoma and other malignancies.
Major finding: The vaccine enhanced T-cell immunity to naturally occurring neoantigens and revealed two additional neoantigens per patient.
Data source: Proof-of-principle study of three patients with resected, cutaneous melanoma.
Disclosures: This work was supported by Barnes-Jewish Hospital Foundation, Siteman Cancer Frontier Fund, Our Mark on Melanoma (MOM) Foundation, Come Out Swinging (COS) Foundation, Blackout Melanoma Foundation and the National Cancer Institute.
Although the cells in this study were grown in a specialized laboratory, “as the technology improves, I think this [strategy] will become reproducible and available at other medical centers,” Dr. Linette said.
This work was supported by Barnes-Jewish Hospital Foundation, Siteman Cancer Frontier Fund, Our Mark on Melanoma (MOM) Foundation, Come Out Swinging (COS) Foundation, Blackout Melanoma Foundation and the National Cancer Institute.
Heidi Splete contributed to this story.
,
